Targeting RSK2 in Myeloid Leukemia: Right for FLT3 but Wrong for BCR-ABL

Cell Cycle - United States
doi 10.4161/cc.10.21.17833
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Acute Myeloid Leukemia With BCR/ABL Fusion Chimera

Indian Journal of Hematology and Blood Transfusion
Hematology
2014English

Targeting BTK for the Treatment of FLT3-ITD Mutated Acute Myeloid Leukemia

Scientific Reports
Multidisciplinary
2015English

Fluorescent In-Situ Hybridization (FISH) for BCR/ABL in Chronic Myeloid Leukemia After Bone Marrow Transplantation

Sao Paulo Medical Journal
Medicine
2001English

Rational for Targeting the Hedgehog Signalling Pathway in Acute Myeloid Leukemia With FLT3 Mutation

Annals of Translational Medicine
Medicine
2016English

Bcr: A Negative Regulator of the BCR-Abl Oncoprotein in Leukemia

Oncogene
Cancer ResearchGeneticsMolecular Biology
2002English

Simultaneous Occurrence of BCR-Abl and Inv16 in a Case of M1 Acute Myeloid Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2001English

Management of Chronic Myeloid Leukemia With BCR/ABL Inhibitors: Current Status and Future Perspectives

Clinical Medicine Insights: Therapeutics
MedicinePharmacologyPharmaceutical Science
2010English

Chronic Myeloid Leukemia With an E1a3 BCR-ABL Fusion Protein: Transformation to Lymphoid Blast Crisis

Biomarker Research
BiochemistryMolecular MedicineClinical Biochemistry
2014English

Adoptive Immunotherapy of BCR-ABL-induced Chronic Myeloid Leukemia-Like Myeloproliferative Disease in a Murine Model

Blood
BiochemistryImmunologyCell BiologyHematology
2004English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy